{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:47:29Z","timestamp":1786978049545,"version":"build-2736575974"},"reference-count":43,"publisher":"Informa UK Limited","issue":"6","license":[{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"funder":[{"name":"argenx, Inc"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Current Medical Research and Opinion"],"published-print":{"date-parts":[[2026,6,3]]},"DOI":"10.1080\/03007995.2026.2700048","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T09:27:16Z","timestamp":1784885236000},"page":"1165-1177","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Clinical efficacy and cost per improved outcome of treatments for generalized myasthenia gravis: evidence from a network meta-analysis and cost-per-responder analysis"],"prefix":"10.1080","volume":"42","author":[{"given":"A. Gordon","family":"Smith","sequence":"first","affiliation":[{"name":"Department of Neurology, Virginia Commonwealth University","place":["Richmond, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali A.","family":"Habib","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of California, Irvine Medical Center","place":["Irvine, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia Z.","family":"Qi","sequence":"additional","affiliation":[{"name":"argenx","place":["Ghent, Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongbo","family":"Yang","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc.","place":["Boston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandy","family":"Du","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc.","place":["Boston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Chen","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc.","place":["Boston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Heerlein","sequence":"additional","affiliation":[{"name":"argenx","place":["Ghent, Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Gelinas","sequence":"additional","affiliation":[{"name":"argenx","place":["Ghent, Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn","family":"Phillips","sequence":"additional","affiliation":[{"name":"argenx","place":["Ghent, Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gil I.","family":"Wolfe","sequence":"additional","affiliation":[{"name":"Department of Neurology, University at Buffalo\/SUNY","place":["Buffalo, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"key":"e_1_3_8_2_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI179742"},{"key":"e_1_3_8_3_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10112235"},{"key":"e_1_3_8_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-019-0079-y"},{"key":"e_1_3_8_5_1","doi-asserted-by":"publisher","DOI":"10.3390\/cells8070671"},{"key":"e_1_3_8_6_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11061597"},{"key":"e_1_3_8_7_1","doi-asserted-by":"publisher","DOI":"10.3233\/JND-170294"},{"key":"e_1_3_8_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0000000000000858"},{"key":"e_1_3_8_9_1","unstructured":"Tice JA Touchette DR Nikitin D et al. Eculizumab and efgartigimod for the treatment of myasthenia gravis: effectiveness and value: institute for Clinical and Economic Review; 2021. Available from: https:\/\/icer.org\/wp-content\/uploads\/2021\/03\/ICER_Myasthenia-Gravis_Final-Report_102021-1.pdf"},{"key":"e_1_3_8_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/ene.15872"},{"key":"e_1_3_8_11_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2024.1479685"},{"key":"e_1_3_8_12_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-05751-1"},{"key":"e_1_3_8_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-024-01062-7"},{"key":"e_1_3_8_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-024-03014-5"},{"key":"e_1_3_8_15_1","unstructured":"Amgen. FDA approves Uplizna for adults with generalized myasthenia gravis. 2025. Available from: https:\/\/www.amgen.com\/newsroom\/press-releases\/2025\/12\/fda-approves-uplizna-for-adults-with-generalized-myasthenia-gravis"},{"key":"e_1_3_8_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00159-9"},{"key":"e_1_3_8_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2100066"},{"key":"e_1_3_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(23)00077-7"},{"key":"e_1_3_8_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(23)00080-7"},{"key":"e_1_3_8_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2501561"},{"key":"e_1_3_8_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(24)00498-8"},{"key":"e_1_3_8_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30369-1"},{"key":"e_1_3_8_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/CND.0000000000000301"},{"key":"e_1_3_8_24_1","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.52.7.1487"},{"key":"e_1_3_8_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1998.tb11015.x"},{"key":"e_1_3_8_26_1","volume-title":"American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting","author":"Li Y","year":"2023","unstructured":"Li Y, Howard JF Jr, Vu T, et\u00a0al. editors. Long-term safety, tolerability, and efficacy of subcutaneous efgartigimod PH20 in patients with generalized myasthenia gravis: interim results of the ADAPT-SC+ study [abstract 222]. Presented at: American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting; November 1-4, 2023. Phoenix, AZ USA."},{"key":"e_1_3_8_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.12142"},{"key":"e_1_3_8_28_1","unstructured":"IBM Watson Health. MicroMedex Red Book. 2026. Available from: https:\/\/www.ibm.com\/products\/micromedex-red-book"},{"key":"e_1_3_8_29_1","unstructured":"Centers for Medicare & Medicaid Services (CMS). Physician fee schedule. 2026. Available from: https:\/\/www.cms.gov\/Medicare\/Medicare-Fee-for-Service-Payment\/PhysicianFeeSched"},{"key":"e_1_3_8_30_1","unstructured":"Qi C Brauer E Gelinas D et\u00a0al. Real-world usage patterns of vyvgart in adults with generalized myasthenia gravis in the United States. 45th Annual carrell-krusen neuromuscular symposium; 2023 February 23\u201324; Dallas TX USA. 2023."},{"key":"e_1_3_8_31_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1280226"},{"key":"e_1_3_8_32_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.790834"},{"key":"e_1_3_8_33_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-025-02859-3"},{"key":"e_1_3_8_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/cns.13110"},{"key":"e_1_3_8_35_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1284444"},{"key":"e_1_3_8_36_1","doi-asserted-by":"publisher","DOI":"10.3233\/JND-150082"},{"key":"e_1_3_8_37_1","volume-title":"Highlights of prescribing information: RYSTIGGO (rozanolixizumab-noli) injection, for subcutaneous use","author":"United States Food and Drug Administration","year":"2025","unstructured":"United States Food and Drug Administration. Highlights of prescribing information: RYSTIGGO (rozanolixizumab-noli) injection, for subcutaneous use. 2025. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/761286s007lbl.pdf"},{"key":"e_1_3_8_38_1","unstructured":"United States Food and Drug Administration. Highlights of prescribing information: ULTOMIRIS (ravulizumab-cwvz) injection for intravenous use. 2023. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761108s023lbl.pdf"},{"key":"e_1_3_8_39_1","unstructured":"United States Food and Drug Administration. Highlights of prescribing information: ZILBRYSQ (zilucoplan). 2024. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/216834s000lbl.pdf"},{"key":"e_1_3_8_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(23)00364-2"},{"key":"e_1_3_8_41_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.809999"},{"key":"e_1_3_8_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-020-00912-8"},{"key":"e_1_3_8_43_1","unstructured":"Dias S Welton NJ Sutton AJ et al. NICE DSU technical support document 2: a generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials. 2011. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK310366\/pdf\/Bookshelf_NBK310366.pdf"},{"key":"e_1_3_8_44_1","unstructured":"Member State Coordination Group on HTA (HTACG). Methodological guideline for quantitative evidence synthesis: direct and indirect comparisons. 2024. Available from: https:\/\/health.ec.europa.eu\/document\/download\/4ec8288e-6d15-49c5-a490-d8ad7748578f_en?filename=hta_methodological-guideline_direct-indirect-comparisons_en.pdf"}],"container-title":["Current Medical Research and Opinion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/03007995.2026.2700048","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/03007995.2026.2700048","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/03007995.2026.2700048","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T13:42:31Z","timestamp":1786974151000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/03007995.2026.2700048"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,3]]},"references-count":43,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6,3]]}},"alternative-id":["10.1080\/03007995.2026.2700048"],"URL":"https:\/\/doi.org\/10.1080\/03007995.2026.2700048","relation":{},"ISSN":["0300-7995","1473-4877"],"issn-type":[{"value":"0300-7995","type":"print"},{"value":"1473-4877","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,3]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=icmo20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=icmo20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-04-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-25","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}